Efficacy and safety of hepatic artery infusion chemotherapy conjunction with tyrosine kinase inhibitors and programmed death-1 inhibitors for unresectable/advanced hepatocellular carcinoma: a meta-analysis
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- European journal of gastroenterology & hepatology
- Publicado em
- 6 jun 2025
- Citações
- 2
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and safety of hepatic artery infusion chemotherapy conjunction with tyrosine kinase inhibitors and programmed death-1 inhibitors for unresectable/advanced hepatocellular carcinoma: a meta-analysis
Yadi Xiao, Xiangbo Tao, Haitao Zhang, Xin Shi, Hongjian Zhao
Descritores MeSH
- Antineoplastic Combined Chemotherapy Protocols
- Immune Checkpoint Inhibitors
- Liver Neoplasms
- Carcinoma, Hepatocellular
- Protein Kinase Inhibitors
- Programmed Cell Death 1 Receptor
- Humans
- Tyrosine Kinase Inhibitors
- Hepatic Artery
- Progression-Free Survival
Veja também
Estudos relacionados
- Efficacy and Safety of HAIC-FOLFOX Plus Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-line Treatment for Unresectable Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
- Hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma: A meta-analysis and trial sequential analysis
- Is PD-1/PD-L1 inhibitor plus bevacizumab superior to sorafenib as first-line treatment for advanced hepatocellular carcinoma? A pooled analysis of four phase 3 RCTs
- Hepatic arterial infusion chemotherapy (HAlC) versus sorafenib for hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) B/C: A systematic review and meta-analysis